Blog Posts

Oct 28, 2024, 10:54

SPCC – Brian Druker reflects on the key milestones of his life and career

SPCC (Sharing Progress in Cancer Care) shared on Linkedin:

”Have you already watched Aleksandra Filipovic’s inspirational interview with Brian Druker, the esteemed director of the OHSU Knight Cancer Institute?

Known for his groundbreaking work in cancer research, Druker developed Gleevec, a targeted therapy that revolutionised the treatment of chronic myeloid leukemia (CML) by attacking cancer cells while preserving healthy ones.

In the interview, Druker reflects on the key milestones of his life and career, from his early days to his present work.

Every new drug has a human who has championed it to existence, who persevered, who believed. Who knew the ‘Why’ and therefore found the ‘How’.

Watch it now.”

Aleksandra Filipovic Brian Druker cancer Cancer research Chronic myeloid leukemia (CML) CML OHSU Knight Cancer Institute OncoDaily Oncology SPCC (Sharing Progress in Cancer Care)

Padraic O’Malley: Meet the Experts of VIRO 2025

Hidden Risks: BRCA Mutations and Breast Implants - CancerWorld

FDA Breakthrough Therapy Designation for Iza-bren: Advancing Treatment for EGFR-Mutant NSCLC

Neil Ranasinghe: What’s the Difference Between a Clinician and a Technical Author?

LOCKTAC Molecular Glues Are Changing the Rules of Drug Discovery - Amgen